Vaccines
Targeting the Greatest Threats in Infectious Disease
Our global vaccine business is applying innovation to address some of the world’s most challenging infectious diseases. By leveraging global, regional and local partnerships, we help to prevent illness and prepare for future threats, as well as support and increase access to medicine.
Vaccines represent a new dimension of global impact for Takeda. We are reaching more people and saving more lives than ever before, and this is an extraordinary privilege, responsibility and opportunity for all of us. Together, we are building on Takeda’s long history and developing a strong pipeline for the future.
To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.
To protect the health of people everywhere through vaccines that address the most important infectious diseases.
In our day-to-day work, all over the world, we focus on the following values while upholding the highest ethical standards:
- Integrity
- Perseverance
- Fairness
- Honesty
- BLB-750 (H5N1 Flu)
- Measles Rubella
- Mumps
- Diphtheria Tetanus Toxoid
- Seasonal Flu (Denka & Kaketsuken)
- Varicella (Biken)
- Japanese Encephalitis (Biken)
Vaccines represent a new dimension of global impact - successful leadership at Takeda can be encompassed in these four pillars:
DEMONSTRATING strategic enterprise thinking, finding innovative ways to serve patients and build trust, reputation and business
CREATING the environment that inspires and enables people to move the organization forward
FOCUSING on the few priorities and delivers superior results
ELEVATING the capabilities of the organization for now and the future
Strategic Priorities
There are two priorities for VBU employees: developing new vaccines to meet unmet health needs and making sure they’re available and accessible to people who need them most.
Our Vaccine Pipeline
We have developed a pipeline that focuses on diseases that impact disproportionally low- and middle-income countries. Currently, our vaccine research is focused on dengue, zika and norovirus.
Preclinical
- Chikungunya Vaccine
(TAK-503)
PHASE 1
- ZIKA VACCINE
(TAK-426) - ENTEROVIRUS VACCINE
(TAK-021)
phase 2
- Norovirus Vaccine
(TAK-214)
phase 3
- Dengue Vaccine
(TAK-003)
View All Vaccines Jobs
SearchKey Locations
- Cambridge, MA (HQ) | Global VBU HQ Operations
- Zurich (HQ)
- Singapore
- Osaka/Tokyo (HQ)
- São Paulo
- Singen
- Hikari
